GlassScriptPhysician profile
Sandeep A Soni
NPI 1285716332
$7,883.22
in general payments reported to CMS, 2019-2025
19 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $751 · 2021: $962 · 2022: $1,213 · 2023: $1,380 · 2024: $1,418 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.02 |
| Education | $201.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,521.33 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $1,206.76 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Gilead Sciences, INC. | $993.81 | 2019-2025 | Biktarvy, Veklury |
| Abbvie INC. | $650.71 | 2021-2025 | Dalvance, Avycaz, Mavyret |
| Astellas Pharma US INC | $565.41 | 2019-2025 | Cresemba, Lexiscan |
| Allergan, INC. | $458.05 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $454.99 | 2020-2025 | Nuzyra |
| Shionogi INC | $415.41 | 2021-2025 | Fetroja |
| Aimmune Therapeutics, INC. | $367.20 | 2023-2024 | |
| Melinta Therapeutics, LLC | $275.22 | 2022-2023 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Biotech, INC. | $206.57 | 2019-2021 | |
| Janssen Products, LP | $188.95 | 2019-2021 | |
| Theratechnologies INC. | $172.93 | 2023-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Cumberland Pharmaceuticals, INC. | $161.23 | 2019-2023 | Vibativ |
| Ferring Pharmaceuticals INC. | $90.47 | 2023-2024 | Rebyota |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $79.08 | 2023-2025 | Xerava, Zevtera |
| Tactile Systems Technology INC | $32.90 | 2019-2020 | |
| Biomerieux INC | $21.91 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $20.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.